Dynavax Technologies Corporation
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also devel… Read more
Dynavax Technologies Corporation (DVAX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.063x
Based on the latest financial reports, Dynavax Technologies Corporation (DVAX) has a cash flow conversion efficiency ratio of 0.063x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($33.83 Million) by net assets ($534.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Dynavax Technologies Corporation - Cash Flow Conversion Efficiency Trend (2002–2024)
This chart illustrates how Dynavax Technologies Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Dynavax Technologies Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dynavax Technologies Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Trump Media & Technology Group Corp.
NASDAQ:DJT
|
0.007x |
|
CNNC Hua Yuan Titanium Dioxide Co Ltd
SHE:002145
|
0.002x |
|
Netwealth Group Ltd
AU:NWL
|
0.436x |
|
Talos Energy
NYSE:TALO
|
0.048x |
|
Pitney Bowes Inc
NYSE:PBI
|
-0.291x |
|
AVIC (Chengdu) UAS Co. Ltd. A
SHG:688297
|
N/A |
|
PNB Housing Finance Limited
NSE:PNBHOUSING
|
-0.215x |
|
SHANGHAI JUNSHI BIO YC1
F:8SJ
|
N/A |
Annual Cash Flow Conversion Efficiency for Dynavax Technologies Corporation (2002–2024)
The table below shows the annual cash flow conversion efficiency of Dynavax Technologies Corporation from 2002 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $596.80 Million | $66.51 Million | 0.111x | -31.06% |
| 2023-12-31 | $622.07 Million | $100.56 Million | 0.162x | +49.76% |
| 2022-12-31 | $581.01 Million | $62.72 Million | 0.108x | -92.85% |
| 2021-12-31 | $222.37 Million | $335.53 Million | 1.509x | +196.00% |
| 2020-12-31 | $58.69 Million | $-92.25 Million | -1.572x | +89.25% |
| 2019-12-31 | $8.29 Million | $-121.25 Million | -14.626x | -602.51% |
| 2018-12-31 | $63.06 Million | $-131.30 Million | -2.082x | -435.95% |
| 2017-12-31 | $199.55 Million | $-77.52 Million | -0.388x | +67.63% |
| 2016-12-31 | $89.20 Million | $-107.05 Million | -1.200x | -142.56% |
| 2015-12-31 | $187.08 Million | $-92.56 Million | -0.495x | +32.58% |
| 2014-12-31 | $100.48 Million | $-73.74 Million | -0.734x | -133.00% |
| 2013-12-31 | $186.29 Million | $-58.67 Million | -0.315x | +17.45% |
| 2012-12-31 | $114.83 Million | $-43.81 Million | -0.382x | +19.12% |
| 2011-12-31 | $99.88 Million | $-47.12 Million | -0.472x | +52.15% |
| 2010-12-31 | $52.11 Million | $-51.37 Million | -0.986x | +81.27% |
| 2009-12-31 | $6.38 Million | $-33.55 Million | -5.262x | -399.07% |
| 2008-12-31 | $16.16 Million | $-17.04 Million | -1.054x | -28.81% |
| 2007-12-31 | $39.13 Million | $-32.03 Million | -0.819x | -73.81% |
| 2006-12-31 | $79.07 Million | $-37.24 Million | -0.471x | -53.22% |
| 2005-12-31 | $74.36 Million | $-22.86 Million | -0.307x | -151.02% |
| 2004-12-31 | $59.88 Million | $-7.33 Million | -0.122x | -148.62% |
| 2003-12-31 | $-57.20 Million | $-14.41 Million | 0.252x | -0.60% |
| 2002-12-31 | $-56.37 Million | $-14.28 Million | 0.253x | -- |